Keynatinib in Treated Patients With NSCLC and Brain Metastases
Status:
Recruiting
Trial end date:
2022-07-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Keynatinib capsules in
patients with advanced non-small cell lung cancer (NSCLC) with brain metastasis or
progression of brain metastasis after treatment with EGFR inhibitors. As well as, to evaluate
the penetration rate of Keynatinib in the Blood-Brain Barrier (BBB) and its PK
characteristics, and the relationship between exposure levels with efficacy and safety.